Inflammatory Bowel Disease Treatment Market Size & Share 2026-2035

Inflammatory Bowel Disease Treatment Market Size

The global inflammatory bowel disease treatment market was valued at USD 28.1 billion in 2025, rising to USD 29.9 billion in 2026 and USD 50.3 billion by 2035, representing a 6.0% CAGR over 2026–2035.^{[1]Global Market Insights, Inflammatory Bowel Disease Treatment Market Size & Share 2025, gminsights.com} Revenue expansion depends less on broad price inflation than on a treatment mix shift: chronic patients increasingly move from conventional therapy into advanced therapies that require continued maintenance dosing.

Crohn's disease and ulcerative colitis create different treatment economics. Crohn's disease can involve transmural inflammation throughout the gastrointestinal tract, making surgery prevention and durable control central to treatment selection. Ulcerative colitis is limited to the colon but still generates substantial advanced-therapy demand when conventional treatment does not maintain remission. Globally, incident IBD cases reached 375,140 in 2021, 88.3% above the 1990 level; China recorded the largest increase in age-standardized incidence among countries assessed between 1990 and 2021.^{[2]Springer Nature / International Journal of Colorectal Disease, Global regional and national burden of inflammatory bowel disease 1990-2021: Insights from the Global Burden of Disease 2021 September 2024, pmc.ncbi.nlm.nih.gov} In the United States, an estimated 2.4–3.1 million adults live with IBD.

The commercial base remains concentrated in specialty medicines. Prescription medications represented about 71% of estimated annual U.S. IBD healthcare costs of USD 8.5 billion in 2018. New IL-23 inhibitors and oral small molecules are enlarging options for moderate-to-severe disease, while biosimilar competition is reducing the acquisition cost of established anti-TNF and IL-12/23 therapies. Lilly received U.S. approval for mirikizumab in Crohn's disease in January 2025. Johnson & Johnson subsequently received approval for guselkumab in Crohn's disease, with intravenous and subcutaneous induction options.

The epidemiological opportunity is geographically uneven. North America combines high diagnosed prevalence, specialist infrastructure, and high specialty-drug spending, whereas Asia Pacific combines faster incidence growth with more price-sensitive reimbursement environments. Manufacturers therefore face two different requirements: protecting premium positioning in mature markets while pairing lower-cost access models, local reimbursement strategies, or biosimilars with patient-volume expansion elsewhere.

This research document covers the global inflammatory bowel disease treatment market across the historic period of 2022–2024, the 2025 base year, and the 2026–2035 forecast period. It assesses treatment type, drug class, route of administration, distribution channel, regional markets, and the competitive positions of AbbVie, Alvotech, Amgen, Biogen, Boehringer Ingelheim, Celltrion, Dr Falk Pharma, Eli Lilly, Ferring, Johnson & Johnson, ORGANON, Pfizer, Takeda Pharmaceuticals, and UCB.

Key Drivers

Increasing Prevalence of IBD

The expanding IBD population creates durable pharmaceutical demand because both principal conditions require long-term disease control rather than a one-time intervention. The Global Burden of Disease analysis found that incident cases rose sharply from 1990 to 2021, while the fastest age-standardized incidence growth occurred in East Asia. Each newly diagnosed patient may progress through several treatment lines as response diminishes, adverse events occur, or clinical goals shift from symptom control to endoscopic remission.

The U.S. population burden also supports persistent specialty-drug utilization. CDC estimates place the number of adults with IBD at 2.4–3.1 million. This patient base gives payers and providers a strong incentive to use therapies that reduce flare-related care, although prior authorization and step-therapy requirements can delay movement to advanced treatment.

Favorable Reimbursement Policies

Reimbursement determines whether biologic innovation converts into volume. Public and private coverage can broaden access to high-cost treatment, but payer control generally directs initial use toward preferred products, especially once biosimilars become available. This makes interchangeability status, specialty-pharmacy access, and tender positioning commercially material, rather than administrative details.

Biosimilars can also support earlier advanced-therapy use by reducing therapy cost. A clinical review of IBD biosimilars reported major price reductions versus originator wholesale acquisition costs for infliximab and adalimumab biosimilars, alongside increasing penetration in the United States.^{[3]Gastroenterology & Hepatology, Clinical Guide to Navigating the Landscape of Biosimilars for Inflammatory Bowel Disease July 2024, gastroenterologyandhepatology.net} The economic effect is two-sided: lower unit revenue pressures incumbent manufacturers, but lower payer exposure can enlarge the treated population.

Technological Advancements

The therapeutic pipeline has shifted competition from broad immune suppression toward selective mechanisms and delivery convenience. The 2025 American College of Gastroenterology guideline lists anti-TNF therapies, IL-23 inhibitors, and anti-integrin therapies among recommended advanced options for moderate-to-severe Crohn's disease and favors risankizumab over ustekinumab for anti-TNF-experienced patients.^{[4]American College of Gastroenterology, ACG Clinical Guideline: Management of Crohn's Disease 2025, journals.lww.com} Such guidance strengthens the role of comparative evidence in formulary selection.

Oral targeted therapies create a different value proposition from injectable biologics. JAK inhibitors can offer rapid onset and dose flexibility, but their labeled safety warnings constrain use in patients with relevant cardiovascular, thrombotic, malignancy, or infection risks. Delivery innovation is equally consequential: subcutaneous maintenance and, increasingly, subcutaneous induction reduce reliance on infusion capacity and can shift dispensing activity toward specialty retail channels.

Growing Awareness and Earlier Diagnosis

Earlier recognition expands the pool of patients entering structured treatment pathways and may reduce prolonged use of ineffective symptomatic care. Treat-to-target management increasingly uses objective indicators, including fecal calprotectin, to inform escalation. Ferring's OPTIMISE study reported improved outcomes from a fecal-calprotectin-led treat-to-target strategy in mild-to-moderate ulcerative colitis.

The commercial implication is not simply more prescriptions. Earlier diagnosis can move patients into specialist follow-up sooner, making treatment sequencing, monitoring, and long-term adherence more central to product performance. Companies with evidence supporting practical monitoring pathways may gain relevance even in disease stages served largely by established therapies.

Key Restraints

Stringent Regulatory Environment

Advanced IBD therapies face regulatory requirements that affect both adoption and development costs. JAK inhibitors carry boxed warnings involving serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis. These risks do not eliminate demand, but they narrow the clinically appropriate population and strengthen the role of risk stratification in prescribing.

Biosimilar competition also requires more than a low list price. Evidence supporting biosimilarity, switching, and-where applicable-interchangeability is important to payer and pharmacy adoption. Products without a clear substitution pathway may face slower uptake even when their clinical basis is strong.

High Cost of Treatment

Drug spending remains the largest identifiable cost pressure in IBD care. Prescription medicines represented approximately 71% of estimated U.S. IBD healthcare costs in 2018. Specialty therapies may reduce clinical complications for some patients, but their up-front expense makes reimbursement approval and persistence vulnerable to payer controls.

Biosimilars moderate this constraint, although their benefit is mediated by contracting and formulary design. As lower-priced anti-TNF and ustekinumab products become established, originator manufacturers must demonstrate a sufficiently meaningful difference in efficacy, safety, convenience, or treatment durability to avoid price-led substitution.

Safety and administration create the principal limits on simple price competition. JAK inhibitors offer oral convenience but retain class-level safety constraints, whereas injectable biologics have established monitoring and administration pathways. Products that combine evidence-based efficacy with lower treatment burden are better positioned to protect value as reference biologics lose exclusivity.

Inflammatory Bowel Disease Treatment Market Segment Analysis

By Treatment Type

Crohn's Disease

Crohn's disease accounted for 60.9% of the IBD treatment market in 2025. Its share reflects the frequent need for durable control of transmural inflammation, which can progress to strictures, fistulas, and surgery if inadequately managed. The 2025 ACG guideline supports advanced therapy for moderate-to-severe disease, including anti-TNF, IL-23, and anti-integrin options.

The commercial consequence is a comparatively intensive switching market. Patients may cycle across mechanisms after primary nonresponse, loss of response, or safety concerns, creating value for differentiated second-line therapies. However, the availability of low-cost biosimilars also makes weakly differentiated follow-on products vulnerable to formulary displacement.

Ulcerative Colitis

Ulcerative colitis generated substantial demand across both conventional and advanced therapies. The condition includes a large mild-to-moderate population that can be managed with aminosalicylates, but treatment complexity rises sharply for patients who do not maintain remission or who require systemic steroids repeatedly. Guselkumab's 2024 U.S. approval for moderately to severely active ulcerative colitis added a new IL-23 option to an increasingly crowded advanced-therapy setting.

Ulcerative colitis also creates a distinct administration opportunity. Localized disease can support rectal mesalazine or corticosteroid use, while moderate-to-severe disease is increasingly served by oral small molecules and self-administered biologics. This broad route mix limits the ability of any single delivery format to dominate all patients.

By Drug Class

First-line treatment

First-line treatment generated USD 4.3 billion in 2025 and is projected to expand at a 4.5% CAGR through 2035. Its economic role is defined by broad patient volume rather than the per-patient value of advanced biologics.

Aminosalicylates

Aminosalicylates remain foundational for mild-to-moderate ulcerative colitis because they act locally at the colonic mucosa and are available in oral and rectal formats. Ferring markets PENTASA, a mesalazine product, internationally for inflammatory bowel disease.^{[5]Ferring Pharmaceuticals, Our Products: PENTASA, ferring.com} The class is unlikely to capture the revenue intensity of advanced therapies, but its use in maintenance care preserves a large and resilient prescription base.

Corticosteroids

Corticosteroids remain important for short-term flare control but are not suitable for maintenance because cumulative systemic exposure creates safety concerns. Budesonide formulations provide a more localized approach; the Australian Pharmaceutical Benefits Scheme evaluated Budenofalk for Crohn's disease in March 2024. The class therefore serves a clinically necessary but episodic role in the market.

Second-line treatment

Second-line treatment represented 74.4% of market revenue in 2025. This concentration shows that market value is primarily created after conventional treatment is insufficient, rather than at diagnosis alone.

IL inhibitors

IL-12/23 and IL-23 inhibitors are redefining competition in the advanced-therapy segment. Mirikizumab's Crohn's disease approval and guselkumab's approvals in ulcerative colitis and Crohn's disease broadened the set of IL-23-directed choices. The 2025 ACG guideline's preference for risankizumab over ustekinumab in certain anti-TNF-experienced patients gives evidence differentiation direct commercial relevance.

Ustekinumab biosimilars alter the comparison point for the class. Once the IL-12/23 reference product becomes substantially less expensive, newer IL-23 products must justify their cost through treatment outcomes, labeling, or administration advantages rather than target novelty alone.

TNF inhibitors

Anti-TNF agents retain broad clinical familiarity and an extensive biosimilar base. The biosimilar literature identifies substantial price reductions and increasing infliximab and adalimumab biosimilar uptake in IBD practice. That makes anti-TNF treatment a crucial access mechanism, particularly for payers that require a lower-cost biologic before authorizing newer products.

UCB's certolizumab pegol remains approved in the United States for adults with moderately to severely active Crohn's disease who have not responded adequately to conventional therapy.^{[6]UCB, CIMZIA for Crohn's Disease, ucb.com} Its continued relevance illustrates that established products can retain specific clinical roles despite intensive class competition.

JAK inhibitors

Tofacitinib and upadacitinib supply oral options for advanced IBD care. Their attraction lies in avoiding injections and enabling relatively rapid pharmacologic adjustment, but safety warnings constrain broad use. AbbVie reported 2024 global net revenues of USD 5.971 billion for Rinvoq across indications, demonstrating the commercial scale that oral immunology therapies can attain.

The treatment decision is therefore not a simple oral-versus-injectable choice. For appropriate patients, oral administration can reduce treatment burden; for patients with relevant risk factors, the safety profile may favor another mechanism despite less convenient administration.

Anti-integrin

Vedolizumab occupies a differentiated position through gut-selective inhibition of the a4b7 integrin pathway. Takeda reported FY2024 ENTYVIO revenue of JPY 914.1 billion, with growth supported by broad immunology demand across indications. Subcutaneous administration can reduce reliance on infusion visits for maintenance therapy, strengthening its relevance where care systems favor home treatment.

S1P receptor modulator

S1P receptor modulators provide another oral mechanism for ulcerative colitis. Their lymphocyte-trafficking mechanism distinguishes them from JAK inhibitors and offers an option where risk profiles or treatment preferences make other advanced therapies less suitable. Their adoption will depend on placement in treatment algorithms, payer access, and evidence of durable real-world outcomes.

Combination therapy

Combination therapy was valued at USD 2.9 billion in 2025 and is projected to grow at a 5.6% CAGR through 2035. Its role reflects efforts to improve therapeutic durability in patients with difficult-to-control disease.

TNF inhibitors + thiopurines

Anti-TNF therapy combined with thiopurines can reduce immunogenicity and support drug exposure in selected patients. The approach is most consequential when preserving response to a biologic is clinically preferable to immediate switching. Its use must be balanced against the additional safety and monitoring burden of immunomodulation.

Other combination therapies

Dual-target strategies and biologic-small-molecule combinations remain comparatively specialized approaches for refractory disease. Their commercial relevance will depend on whether clinical evidence can establish sufficient benefit to offset cost, safety, and reimbursement complexity.

By Route of Administration

Injectable

Injectable therapies generated USD 23.6 billion in 2025. This position reflects the predominance of biologic antibodies across anti-TNF, IL-23, and anti-integrin classes. Subcutaneous administration is changing the economics of the route by allowing more maintenance care outside infusion centers.

Guselkumab's Crohn's disease approval included both intravenous and subcutaneous induction options. This distinction may matter in payer and provider discussions because it can simplify the care pathway for eligible patients and reduce dependence on infusion capacity.

Oral

Oral therapies combine high-volume conventional treatment with newer advanced options. Aminosalicylates underpin routine outpatient prescribing, while JAK inhibitors and S1P modulators serve selected moderate-to-severe patients. The oral route can improve convenience, but its growth is moderated by safety requirements and by the continuing clinical importance of injectable biologics.

Rectal

Rectal therapies are tailored to localized distal ulcerative colitis and retain clinical relevance because they provide direct mucosal exposure. The route has a narrower patient base and lower average price than systemic advanced therapies, but it remains important in treatment plans that seek to avoid unnecessary systemic escalation.

By Distribution Channel

Hospital pharmacy

Hospital pharmacies accounted for 61.8% of IBD treatment revenue in 2025. Their role reflects infusion requirements, cold-chain handling, prior authorization management, and the concentration of complex IBD care in specialist settings. This channel is especially important for induction regimens and patients who require close monitoring.

Retail pharmacy

Retail and specialty pharmacies are increasingly relevant for oral therapies and self-administered biologics. The shift toward subcutaneous maintenance expands the portion of IBD care that can be dispensed outside hospitals, although specialty distribution controls remain common for high-cost products.

Online pharmacy

Online pharmacy is positioned to benefit from e-prescribing and home delivery for stable maintenance therapy. Its relevance will be greatest where reimbursement systems permit remote dispensing and where specialty-pharmacy services can provide training, monitoring, and adherence support.

Delivery is becoming an important competitive variable. Injectable therapy remains the largest route at USD 23.6 billion, but subcutaneous formulations can shift care away from infusion infrastructure and toward specialty retail fulfillment. Oral agents offer a competing convenience model, although their safety constraints prevent them from universally replacing biologics. Consequently, the most valuable segment positions will be those that align clinical evidence, route preference, and payer economics rather than those based on mechanism alone.

Inflammatory Bowel Disease Treatment Market Regional Analysis

North America

North America held 65.5% of global market revenue in 2025. The region combines high diagnosed prevalence, specialist care, broad availability of advanced therapies, and high specialty-drug expenditure. Biosimilars are beginning to change this revenue structure by lowering the cost of established biologics, but advanced branded therapies continue to command value where clinical differentiation is recognized.

United States

The U.S. market was valued at USD 17.4 billion in 2025. An estimated 2.4–3.1 million U.S. adults have IBD, creating a large established treatment population. The market is likely to remain the primary launch setting for new IBD therapies, although prior authorization, rebates, and biosimilar substitution will increasingly influence net realized revenue.

Canada

Canada recorded the highest national age-standardized IBD incidence rate in the 2021 Global Burden of Disease analysis, at 26.83 per 100,000 population. Its substantial disease burden supports advanced-treatment demand, while formulary management and public reimbursement structures make comparative value evidence important to product access.

Europe

Europe was valued at USD 5.6 billion in 2025. The region's commercial structure is shaped by mature specialist care and active biosimilar use. As a result, manufacturers are more likely to compete on demonstrated incremental benefit, tender terms, and service support than on reference-biologic pricing.

Germany

Germany remains a major European opportunity because of its established specialist infrastructure and substantial IBD burden. Companies seeking share must navigate a reimbursement environment in which comparative therapeutic value and negotiated pricing affect access.

United Kingdom

The United Kingdom's centralized health system makes formulary and biosimilar policies influential in product uptake. This environment favors therapies that can show a credible improvement in outcomes, administration burden, or total treatment cost.

France

France's hospital-centered specialist treatment pathways make provider experience and institutional formulary decisions important for advanced IBD therapies. Biosimilar adoption reinforces the need for branded entrants to establish a clear clinical rationale.

Spain

Spain's regionalized health administration can create variation in access pathways and procurement decisions. The country's experience with biosimilars makes price and supply reliability especially relevant to market participation.

Italy

Italy's specialist gastroenterology centers concentrate much of the advanced-therapy decision-making. Manufacturers must therefore pair national reimbursement support with strong evidence and implementation capabilities at major treatment centers.

Netherlands

The Netherlands had the highest IBD-associated age-standardized disability-adjusted life-year rate in Western Europe in 2021, at 74.96 per 100,000 population. Its established clinical-research and biosimilar environment favors evidence-based treatment optimization over brand loyalty alone.

Asia Pacific

Asia Pacific is projected to record a 7.6% CAGR through 2035. The region's expansion is driven by rising diagnosed incidence, growing specialist capacity, and progressive access to biologics. The central constraint is affordability: patient volume can increase rapidly, but revenue per treated patient may remain below North American levels where price controls and local competition are stronger.

China

China recorded the largest national increase in age-standardized IBD incidence between 1990 and 2021. As diagnosis and reimbursement pathways develop, the market can become a major source of patient-volume growth. Local biosimilar availability and price-sensitive procurement are likely to determine whether expansion favors multinational innovators or lower-cost alternatives.

Japan

Japan has an established advanced-therapy environment and a sizeable ulcerative colitis treatment population. Its mature clinical infrastructure supports adoption of new mechanisms, but access will continue to depend on evidence of clinical value and local treatment practice.

India

India's opportunity is anchored in diagnosis growth and expanding urban specialist care, but affordability remains a binding constraint. Biosimilars and lower-cost treatment pathways are therefore likely to reach more patients than high-priced originator biologics outside private specialty settings.

Australia

Australia's structured reimbursement environment supports specialist-directed use of advanced therapy. The PBS considered Budenofalk for Crohn's disease in March 2024, illustrating the role of public reimbursement decisions in shaping access even for established gastrointestinal medicines.

South Korea

South Korea's advanced hospital infrastructure and participation in international clinical research support adoption of modern IBD treatment approaches. National reimbursement conditions will remain decisive in determining the pace at which newer high-cost therapies move beyond specialist centers.

Latin America

Latin America combines growing urban diagnosis with uneven access to advanced treatment. The principal commercial issue is not disease relevance but the ability of public systems and private payers to fund biologics at scale. Biosimilars can materially expand access when tender and distribution systems support reliable supply.

Brazil

Brazil is the region's most important IBD market because of its population scale and growing specialty-care capacity. Access remains uneven between major urban treatment centers and other areas, increasing the value of products that can be distributed reliably through public and private channels.

Mexico

Mexico's market is supported by improved diagnosis and specialty-care development, but affordability restricts per-patient biologic spending. Companies must therefore balance innovative launches with cost-sensitive access strategies.

Argentina

Argentina has an established medical research community but faces purchasing-power volatility that can disrupt high-cost medicine access. Supply continuity and payer engagement are essential competitive considerations.

Middle East and Africa

Middle East and Africa remains a developing IBD market where diagnosis infrastructure and specialist availability vary widely. The market is likely to develop first in higher-income healthcare systems and private-care settings before broader access becomes established.

South Africa

South Africa's advanced IBD therapy use is concentrated in private-sector care, leaving a material access divide between private and public patients. Lower-cost biologics may be particularly relevant if reimbursement pathways broaden.

Saudi Arabia

Saudi Arabia's investment in hospital capacity and specialist services can support greater IBD diagnosis and treatment intensity. Market development will depend on the integration of advanced therapies into public purchasing and clinical pathways.

UAE

The UAE's private healthcare infrastructure supports comparatively early access to specialty therapies. Its role as a regional care hub can make physician education, specialist networks, and reliable distribution important elements of market entry.

Europe offers the clearest warning for originator manufacturers: mature biosimilar use changes the threshold for premium adoption. In emerging markets, biosimilars may instead create the conditions for biologic market formation. Companies that can segment their evidence, access, and distribution models by region are better placed than those that rely on a uniform global pricing proposition.

Inflammatory Bowel Disease Treatment Market Share & Competitive Landscape

Competition spans branded innovators, established specialty-gastroenterology suppliers, and biosimilar specialists. The key competitive question is increasingly whether a product can defend a position through clinical differentiation, administration convenience, or substitution economics.

AbbVie

AbbVie's IBD position centers on Skyrizi and Rinvoq, which offer different mechanisms and administration profiles for advanced disease. AbbVie reported 2024 global net revenues of USD 11.718 billion for Skyrizi and USD 5.971 billion for Rinvoq across indications. Its strategy is to replace declining Humira revenue with products that retain greater exclusivity and guideline-supported relevance in IBD.

Alvotech

Alvotech participates through interchangeable biosimilars. SIMLANDI received U.S. approval in February 2024 as an interchangeable, high-concentration, citrate-free adalimumab biosimilar.^{[7]Alvotech Investors, Alvotech and Teva Announce U.S. Approval of SIMLANDI (adalimumab-ryvk) February 2024, investors.alvotech.com} Its partnership model with Teva provides commercialization reach in a segment where pharmacy substitution and payer contracting can be more decisive than brand promotion.

Amgen

Amgen's IBD biosimilar activity includes Amjevita and Wezlana. Wezlana launched as an interchangeable ustekinumab biosimilar in the United States in 2025. Interchangeability can improve its access where pharmacy-level substitution is permitted, making its competitive value tied closely to formulary design.

Biogen

Biogen's historical biosimilar activity with Samsung Bioepis has included anti-TNF products in Europe. Its role illustrates the importance of development, regulatory, and commercialization partnerships in biosimilars, where portfolio depth and market access capabilities determine whether clinical comparability translates into share.

Boehringer Ingelheim

Boehringer Ingelheim markets Cyltezo, an interchangeable adalimumab biosimilar. The product's switching evidence and interchangeability status position it for payer-driven use in markets where adalimumab remains a common entry biologic.

Celltrion

Celltrion is expanding from anti-TNF biosimilars into ustekinumab competition. STEQEYMA received U.S. FDA approval in December 2024.^{[8]Celltrion, U.S. FDA Approves Celltrion's STEQEYMA December 2024, celltrion.com} Its ability to offer lower-cost alternatives across multiple biologic categories strengthens its relevance as payers seek to reduce IBD treatment expenditure.

Dr Falk Pharma

Dr Falk Pharma remains focused on foundational gastrointestinal treatment. Budenofalk supplies a targeted budesonide option for Crohn's disease and was evaluated for Australian PBS reimbursement in 2024. Its competitive position is concentrated in first-line and localized therapy rather than in the high-revenue advanced-biologic segment.

Eli Lilly

Lilly's Omvoh became a Crohn's disease treatment option following U.S. approval in January 2025. The product gives Lilly a direct role in the IL-23 competition, where long-term differentiation will depend on comparative outcomes, treatment durability, and practical administration.

Ferring

Ferring's IBD franchise includes PENTASA and clinical work supporting treat-to-target management. The OPTIMISE study's fecal-calprotectin-led approach reinforces the company's relevance in earlier-stage ulcerative colitis management, where monitoring and adherence can influence escalation decisions.

Johnson & Johnson

Johnson & Johnson is transitioning from Stelara toward Tremfya as ustekinumab biosimilars enter the market. Tremfya's U.S. Crohn's disease approval included both intravenous and subcutaneous induction options. This delivery flexibility, together with its IL-23 mechanism, is central to J&J's effort to preserve branded immunology value after Stelara's exclusivity loss.

ORGANON

ORGANON commercializes HADLIMA, an adalimumab biosimilar developed by Samsung Bioepis. The FDA granted interchangeability designation for HADLIMA high-concentration presentations in May 2025. The designation supports the company's positioning in pharmacy and payer channels where substitution can accelerate biosimilar adoption.

Pfizer

Pfizer participates through the oral JAK inhibitor Xeljanz for ulcerative colitis, as well as biosimilar products. Its acquisition of Arena Pharmaceuticals added etrasimod, broadening Pfizer's interest in oral immunology therapies for ulcerative colitis. This combined approach gives Pfizer exposure to both branded oral innovation and price-sensitive biologic substitution.

Takeda Pharmaceuticals

Takeda's principal IBD product is ENTYVIO. Takeda reported FY2024 ENTYVIO revenue of JPY 914.1 billion, supported by continued growth in its global immunology franchise. The subcutaneous formulation broadens the treatment setting beyond infusion-based maintenance and provides a practical defense against competing biologics.

UCB

UCB's IBD role is concentrated in CIMZIA for Crohn's disease. The product is approved in the United States for adults with moderately to severely active Crohn's disease who have responded inadequately to conventional therapy. Its differentiated Fc-free format sustains a defined role within a crowded anti-TNF category.

Recent Industry Developments

September 2025: The FDA approved a fully subcutaneous induction regimen for Tremfya in adults with moderately to severely active ulcerative colitis, expanding Johnson & Johnson's administration options across IBD indications.

June 2025: The European Commission authorized Celltrion's Qoyvolma, a ustekinumab biosimilar, for European Union marketing.

May 2025: Teva and Alvotech received FDA approval for SELARSDI as an interchangeable biosimilar to ustekinumab for Crohn's disease and ulcerative colitis.

May 2025: Samsung Bioepis and ORGANON received FDA interchangeability designation for HADLIMA high-concentration presentations.

April 2025: The European Commission approved Tremfya for adults with moderately to severely active ulcerative colitis.

March 2025: The FDA approved Tremfya for adults with moderately to severely active Crohn's disease.

January 2025: The FDA approved Omvoh for moderately to severely active Crohn's disease.

December 2024: The FDA approved Celltrion's STEQEYMA as a biosimilar to Stelara.

December 2024: Takeda withdrew Alofisel from the European Union market following results from the ADMIRE-CD II study.